Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Lebein, a Snake Venom Disintegrin, Induces Apoptosis in Human Melanoma Cells.

Hammouda MB, Montenegro MF, Sánchez-Del-Campo L, Zakraoui O, Aloui Z, Riahi-Chebbi I, Karoui H, Rodríguez-López JN, Essafi-Benkhadir K.

Toxins (Basel). 2016 Jul 5;8(7). pii: E206. doi: 10.3390/toxins8070206.

2.

Single Heteroatom Fine-Tuning of the Emissive Properties in Organoboron Complexes with 7-(Azaheteroaryl)indole Systems.

Más-Montoya M, Usea L, Espinosa Ferao A, Montenegro MF, Ramírez de Arellano C, Tárraga A, Rodríguez-López JN, Curiel D.

J Org Chem. 2016 Apr 15;81(8):3296-302. doi: 10.1021/acs.joc.6b00265. Epub 2016 Mar 29.

PMID:
26991893
3.

Promoting E2F1-mediated apoptosis in oestrogen receptor-α-negative breast cancer cells.

Montenegro MF, Collado-González Mdel M, Fernández-Pérez MP, Hammouda MB, Tolordava L, Gamkrelidze M, Rodríguez-López JN.

BMC Cancer. 2014 Jul 26;14:539. doi: 10.1186/1471-2407-14-539.

4.

Effects of a synthetic antitumoral catechin and its tyrosinase-processed product on the structural properties of phosphatidylcholine membranes.

How CW, Teruel JA, Ortiz A, Montenegro MF, Rodríguez-López JN, Aranda FJ.

Biochim Biophys Acta. 2014 May;1838(5):1215-24. doi: 10.1016/j.bbamem.2014.01.025. Epub 2014 Feb 8.

5.

Suppression of antifolate resistance by targeting the myosin Va trafficking pathway in melanoma.

Fernández-Pérez MP, Montenegro MF, Sáez-Ayala M, Sánchez-del-Campo L, Piñero-Madrona A, Cabezas-Herrera J, Rodríguez-López JN.

Neoplasia. 2013 Jul;15(7):826-39.

6.

Directed phenotype switching as an effective antimelanoma strategy.

Sáez-Ayala M, Montenegro MF, Sánchez-Del-Campo L, Fernández-Pérez MP, Chazarra S, Freter R, Middleton M, Piñero-Madrona A, Cabezas-Herrera J, Goding CR, Rodríguez-López JN.

Cancer Cell. 2013 Jul 8;24(1):105-19. doi: 10.1016/j.ccr.2013.05.009. Epub 2013 Jun 20.

7.

Reactivation of the tumour suppressor RASSF1A in breast cancer by simultaneous targeting of DNA and E2F1 methylation.

Montenegro MF, Sáez-Ayala M, Piñero-Madrona A, Cabezas-Herrera J, Rodríguez-López JN.

PLoS One. 2012;7(12):e52231. doi: 10.1371/journal.pone.0052231. Epub 2012 Dec 14.

8.

Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance.

Sáez-Ayala M, Fernández-Pérez MP, Montenegro MF, Sánchez-del-Campo L, Chazarra S, Piñero-Madrona A, Cabezas-Herrera J, Rodríguez-López JN.

Exp Cell Res. 2012 Jun 10;318(10):1146-59. doi: 10.1016/j.yexcr.2012.03.022. Epub 2012 Mar 29.

PMID:
22484375
9.

Comparison of a pair of synthetic tea-catechin-derived epimers: synthesis, antifolate activity, and tyrosinase-mediated activation in melanoma.

Sáez-Ayala M, Sánchez-del-Campo L, Montenegro MF, Chazarra S, Tárraga A, Cabezas-Herrera J, Rodríguez-López JN.

ChemMedChem. 2011 Mar 7;6(3):440-9. doi: 10.1002/cmdc.201000482. Epub 2011 Feb 7.

PMID:
21302360
10.

Mechanism of dihydrofolate reductase downregulation in melanoma by 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin.

Sánchez-del-Campo L, Chazarra S, Montenegro MF, Cabezas-Herrera J, Rodríguez-López JN.

J Cell Biochem. 2010 Aug 15;110(6):1399-409. doi: 10.1002/jcb.22656.

PMID:
20564235
11.

The critical role of alpha-folate receptor in the resistance of melanoma to methotrexate.

Sánchez-del-Campo L, Montenegro MF, Cabezas-Herrera J, Rodríguez-López JN.

Pigment Cell Melanoma Res. 2009 Oct;22(5):588-600. doi: 10.1111/j.1755-148X.2009.00586.x. Epub 2009 Jun 2.

PMID:
19493312
12.

Melanoma activation of 3-o-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin to a potent irreversible inhibitor of dihydrofolate reductase.

Sánchez-del-Campo L, Tárraga A, Montenegro MF, Cabezas-Herrera J, Rodríguez-López JN.

Mol Pharm. 2009 May-Jun;6(3):883-94. doi: 10.1021/mp800259k.

PMID:
19358568
13.

Hydrolysis of acetylthiocoline, o-nitroacetanilide and o-nitrotrifluoroacetanilide by fetal bovine serum acetylcholinesterase.

Montenegro MF, Moral-Naranjo MT, Muñoz-Delgado E, Campoy FJ, Vidal CJ.

FEBS J. 2009 Apr;276(7):2074-83. doi: 10.1111/j.1742-4658.2009.06942.x.

14.

Human butyrylcholinesterase components differ in aryl acylamidase activity.

Montenegro MF, María TM, de la Cadena MP, Campoy FJ, Muñoz-Delgado E, Vidal CJ.

Biol Chem. 2008 Apr;389(4):425-32. doi: 10.1515/BC.2008.041.

PMID:
18208347

Supplemental Content

Loading ...
Support Center